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Abstract
Objective: Medications commonly used to treat heart disease, anxiety, and depression can interact resulting in an increased
risk of bleeding, warranting a cautious approach in medical decision making. This retrospective, descriptive study examined
the prevalence and the factors associated with the use of both selective-serotonin reuptake inhibitor and platelet aggregation
inhibitor among individuals with co-occurring atherosclerotic cardiovascular disease and anxiety or depression.
Methods: Respondents aged 22 years and older, alive throughout the study period, and diagnosed with co-occurring
atherosclerotic cardiovascular disease and anxiety or depression (n = 1507) in years 2007 through 2013 of the Medical
Expenditures Panel Survey were included. The use of treatment was grouped as follows: selective-serotonin reuptake
inhibitor and platelet aggregation inhibitor, selective-serotonin reuptake inhibitor or platelet aggregation inhibitor, and
neither selective-serotonin reuptake inhibitor nor platelet aggregation inhibitor.
Results: Overall, 16.5% used both selective-serotonin reuptake inhibitor and platelet aggregation inhibitor, 61.2% used
selective-serotonin reuptake inhibitor or platelet aggregation inhibitor, and 22.3% used neither selective-serotonin reuptake
inhibitor nor platelet aggregation inhibitor. Respondents aged over 65 years (adjusted odds ratio = 1.93 (95% confidence
interval = 1.08–3.45)) and having a diagnosis of diabetes (adjusted odds ratio = 1.63 (95% confidence interval = 1.15–2.31))
and hypertension (adjusted odds ratio = 1.84 (95% confidence interval = 1.04–3.27)) were more likely to be prescribed the
combination.
Conclusion: The drug interaction was prevalent in patients who are already at higher risk of health disparities and worse
outcomes thus requiring vigilant evaluation.
Keywords
Pharmacoepidemiology/drug safety, survey research, drug interaction
Date received: 14 April 2016; accepted: 17 October 2016

Background
Anxiety and depression are highly prevalent in individuals
with heart disease.1–3 Anxiety disorders are the most common
mental illnesses in the United States with 31% estimated lifetime prevalence.4 An estimated 6.7% of adults experienced an
episode of depression, a potentially debilitating mental illness, in a typical 12-month period.5 Among individuals with
coronary heart disease, 36% were found to have anxiety disorder.2 The 12-month prevalence of major depression was
estimated at 9.3% for patients with coronary heart disease.6
Platelet aggregation inhibitors (PAIs) are a cornerstone of
treatment for atherosclerotic cardiovascular disease (ASCVD)

including secondary prevention and risk reduction for coronary artery disease (CAD),7 peripheral artery disease (PAD),8
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and acute coronary syndromes (ACS) with percutaneous coronary intervention (PCI)9 or coronary artery bypass graft
(CABG).10 Adverse effects of PAIs can include major or minor
bleeding, gastrointestinal bleeding, hematoma, and less frequently, hemorrhagic stroke.11,12 PAI are also used for secondary prevention and risk reduction for CADs.9,13
Selective-serotonin reuptake inhibitors (SSRIs) are firstline therapy for anxiety disorders including generalized
anxiety disorder, post-traumatic stress disorder,14 obsessivecompulsive disorder,15 and panic disorders.16 SSRIs are also
potential first-line therapies for mild, moderate, or severe
major depressive disorder (MDD). The evidence for depression treatment affecting cardiovascular outcomes is the
Enhancing Recovery in Coronary Heart Disease (ENRICHD)
study which had a post hoc finding that a subset of patients
receiving an SSRI had better outcomes.17
Among patients with ASCVD and depression or anxiety,
some patients may be treated with an SSRI and a PAI. When
these medications are given in combination, platelet aggregation may be impaired and the risk of bleeding events can be
increased.18,19 These events include stomach bleeding, bruising, nose bleeding, and other serious internal or external
bleeding. This interaction has been assessed in non-US populations to show that SSRIs increased the risk of lower gastrointestinal bleeds (distal to the ligament of Treitz),20 and the
combined use of a PAI with an SSRI is associated with an
increased risk of bleeding.21 Therefore, it is important to monitor individuals with this medication combination. However,
the extent to which SSRI/PAI combination occurs in realworld practice settings is not known. Furthermore, no study
has assessed subgroup differences in SSRI/PAI combination
use among adults with co-occurring ASCVD and anxiety or
depression in the United States. Therefore, the primary objective of this study was to estimate the prevalence of SSRI/PAI
combination among adults with co-occurring ASCVD and
anxiety or depression. The secondary objective was to analyze
subgroup differences in individuals using SSRI/PAI combination compared to those who received either SSRI or PAI.

Conceptual framework
Factors associated with SSRI/PAI use categories were guided
by the Andersen expanded behavioral model for use of health
services.22 This model states that healthcare treatments are
affected by (1) an individual’s predisposing factors, (2) the
factors which enable individuals to receive services, (3) the
individual’s level of need for the healthcare services, (4) personal health practices, and (5) the external healthcare environment. In this study, predisposing factors consisted of
gender, race, and age; enabling factors included education,
poverty status as a percentage of the federal poverty line
(FPL), health insurance coverage, and prescription drug coverage; and need factors were perceived physical and mental
health of the individuals as well as presence of diabetes or
hypertension. Personal health practices included obesity
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measured with body mass index (BMI), exercise frequency,
and smoking status. The external healthcare environment
was represented by geographic region.

Methods
Study design
This is a retrospective, cross-sectional study designed to analyze patterns of SSRI/PAI combination use among adults
with co-occurring ASCVD and anxiety or depression. In this
study, ASCVD included ACS, history of myocardial infarction, angina (stable or unstable), arterial revascularization, or
peripheral arterial disease related to atherosclerosis.23

Data source
This study used the Medical Expenditures Panel Survey
(MEPS), a publicly available, nationally representative (of
the civilian, non-institutionalized population) set of surveys.24 MEPS data are released in full-year consolidated
household files, medical conditions, prescription drug
events, and others. Full-year consolidated household files
contain individual-level data on demographics, healthcare
expenditures, healthcare use, sources of payments, and
health insurance coverage. The Medical Conditions files
contain information on conditions taken from respondents
which were coded to International Classification of Disease,
9th Edition, Clinical Modification (ICD-9-CM) codes by
professional coders then were converted by Agency for
Healthcare Research and Quality (AHRQ) to clinical classification codes. The information in the Prescribed
Medicines files are at the event-level, and each record is a
unique prescribed medicine including national drug code
(NDC), medicine name, and any conditions reported with
the prescription processing. NDCs were mapped to a therapeutic class based on Multum Lexicon therapeutic classification system and were made available to the researchers in
the MEPS.25

Analytical sample
Individuals aged 22 years or older, alive during the calendar
year, had co-occurring ASCVD and anxiety or depression
were included in the sample for the analysis. ASCVD was
identified using three-digit ICD-9-CM codes from the medical conditions files of the MEPS. We restricted the analysis
to those with ASCVD because PAIs are used in these conditions. ASCVD were identified using the following ICD9-CM codes as has been done in the previous research:26–29
410.x, 411.x, 412.x, 413.x, 414.x, 429.x, 440.x, and 443.x.
Anxiety was defined with clinical classification code 651
and mood disorders were determined with clinical classification code 657. The analytical sample consisted of 1,507
unique individuals (Figure 1).
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Figure 1. Final study sample: inclusion and exclusion criteria of the Medical Expenditures Panel Survey, 2007, 2009, 2011, and 2013.
MEPS: Medical Expenditures Panel Survey; ASCVD: atherosclerotic cardiovascular disease; PAD: peripheral arterial disease; GI: gastrointestinal; SSRI:
selective-serotonin reuptake inhibitors; PAI: platelet aggregation inhibitors.

Measures
Dependent variable
SSRIs and PAIs were identified using the event-level data
from the prescription drug files and were aggregated at the
person-level. Multum-lexicon therapeutic class code of 208
represented SSRIs. Medications in this class included citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine,
and sertraline. PAIs were identified with code 211.
Medications in this category include prescription, oral
agents: clopidogrel, cilostazol, prasugrel, ticagrelor, and
ticlopidine. SSRI and PAI use was combined to yield the
following three categories: (1) SSRI and PAI, (2) SSRI or
PAI, and (3) no SSRI and no PAI.

Independent variables
The independent variables were as follows: gender (male
and female); race (White, African American, and other
minorities); age in years (22–49, 50–64, and ⩾65); education (less than high school, high school, and more than high
school); poverty status (poor, near poor, middle income,
and high income); insurance coverage (private, public, and
uninsured); prescription drug coverage (yes, and no); perceived physical health (excellent/very good, good, and fair/
poor); perceived mental health (excellent/very good, good,
and fair/poor); diagnosis of diabetes (diabetes and no diabetes); diagnosis of hypertension (hypertension and no

hypertension); obesity (underweight/normal, overweight,
and obese); exercise frequency (at least three times per
week and less than three times per week); smoking status
(current smoker, former and non-smoker); and region
(northeast, mid-west, south, and west). There were 19 individuals who had missing data on obesity and 89 individuals
had missing data on smoking status. For these individuals,
we created missing indicators and these were included in
the regression analyses.
Whites and African Americans were identified in the race
variable and Hispanics were identified in the ethnicity variable. These were combined to Whites, African Americans,
Hispanic, and other minorities. However, due to low cell
counts in other minorities, Hispanic and other minorities
were combined. Region categories were based on the census
region at the beginning of the survey period.

Statistical analysis
Unadjusted group differences in SSRI and PAI use categories
were tested with chi-square statistics. As the SSRI and PAI use
consisted of three treatment categories, multinomial logistic
regression was used to analyze patterns of SSRI and PAI use.
The reference group for the dependent variable was “SSRI or
PAI” use. The reference group was chosen because that is the
condition where the SSRI and PAI interaction would not occur,
and the group receiving neither therapy is being potentially
undertreated. The independent variables with corresponding
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Table 1. Characteristics of adults with co-occurring
atherosclerotic cardiovascular disease and depression or anxiety:
Medical Expenditures Panel Survey, 2007, 2009, 2011, and 2013.

Table 1. (Continued)

All

Smoking status+
  Current smoker
   Former or non-smoker
External healthcare environment
Region
  Northeast
  Midwest
  South
  West

Predisposing factors
Gender
  Female
  Male
Race/ethnicity
  White
  African American
  Others
Age (years)
  22–49
  50–64
  ⩾65
Enabling factors
Education level
   Less than high school
   High school graduate
   Greater than high school
Poverty status
   Poor (<100% of FPL)
   Near poor (100%–199% FPL)
   Middle income (200%–399% FPL)
   High income (400% or greater FPL)
Insurance coverage
  Private
  Public
  Uninsured
Prescription drug insurance
  Prescription coverage
   No prescription coverage
Need factors
Perceived physical health
   Excellent or very good
  Good
   Fair or poor
Perceived mental health
   Excellent or very good
  Good
  Fair poor
Diabetes
  Diabetes
  No diabetes
Hypertension
  Hypertension
  No hypertension
Personal health practices
Body mass index categories
   Under weight or normal
  Overweight
  Obese
Exercise frequency
   Three or more times per week
   Less than three times per week

N = 1507

Wt.%

All

N = 1507

Wt.%

360
1058

24.0
70.1

250
341
627
289

17.7
24.1
39.7
18.4

907
600

59.2
40.8

957
240
310

80.3
8.0
11.7

223
586
698

13.9
37.0
49.2

473
521
506

24.4
36.9
38.7

433
427
380
267

20.9
27.3
27.5
24.2

639
778
90

51.7
44.0
4.4

795
712

57.9
42.1

206
404
897

16.3
29.8
53.9

384
552
571

29.7
37.4
33.0

623
883

37.6
62.4

1262
245

82.6
17.4

326
474
688

24.4
30.8
43.8

Description of the sample by SSRI/PAI treatment
categories

409
1090

28.6
71.0

Overall, 16.5% used SSRI/PAI combination, 61.2% used
either SSRI or PAI, and 22.3% used neither SSRI nor PAI.
There were statistically significant differences in SSRI/PAI

FPL: Federal Poverty Line; Wt.: weighted.
Based on adults aged 22 years and older with atherosclerotic cardiovascular disease and either depression or anxiety and without gastrointestinal
bleeding disorders during 2007, 2009, 2011, and 2013.

reference groups are shown in Table 3. For each of the independent variables, adjusted odds ratios (AORs), 95% confidence intervals (CIs), and significance levels from the
multinomial regression are reported. All analyses were conducted considering the complex survey design of MEPS and
using Statistical Analysis Software (SAS®) version 9.4.
We also conducted secondary analyses in which we
included all patients on antidepressants that were not SSRIs
and a PAI as a separate group. It was analyzed using a multinomial logistic regression, so that SSRI/PAI could be compared to non-SSRI antidepressants plus PAI. There were no
significant differences between these groups; therefore, we
do not present these results in this article.

Results
Sample description
Table 1 presents the weighted percent of the characteristics
of the study sample that included individuals with co-occurring ASCVD and anxiety or depression. The majority of the
sample included female (59.2%), Whites (80.3%), and high
school graduates (75.6%). Nearly 50% were aged 65 years
or older. Chronic conditions such as obesity (43.8%), diabetes (37.6%), and hypertension (82.6%) were also prevalent.
Diabetes was diagnosed in our sample more frequently than
the national average of 9.3%.30 An overwhelming majority
(82.6%) had hypertension, and the percentage of current
smokers (24.0%) was higher than the national average of
19% in 201131 and 16.8% in 2014.32

Thornton et al.
treatment categories by race/ethnicity (p < 0.001), age
(p = 0.009), insurance coverage (p = 0.014), diabetes diagnosis (p < 0.001), and hypertension diagnosis (p = 0.001). Full
group differences can be seen in Table 2. A higher percentage
of adults with diabetes (21.6%) used SSRI/PAI combination
compared to adults without diabetes (13.4%).

Multinomial logistic regression on SSRI/PAI
treatment categories
AORs, 95% CIs, and significance levels from multinomial
logistic regression on SSRI and PAI use categories for each
of the independent variable are presented in Table 3. SSRI
and PAI use was more likely among older adults
(age > 65 years) (AOR = 1.93 (95% CI = 1.08–3.45)), those
with diabetes (AOR = 1.63 (95% CI = 1.15–2.31)), and those
with hypertension (AOR = 1.84 (95% CI = 1.04–3.27)) than
among younger adults, those without diabetes, and those
without hypertension.

Discussion
This study sets out to examine the combined use of SSRI and
PAI among adults with co-occurring ASCVD and anxiety or
depression. According to the practice guidelines, SSRIs can
be a reasonable first option for treating anxiety and depression. PAIs are considered a cornerstone of pharmacotherapy
for many types of ASCVD. Although the mechanism is not
clear, many studies have shown that combined use of SSRI
and PAI is associated with an increased risk of bleeding
events.21,33 Therefore, we considered the combined SSRI and
PAI use as treatment to be used with caution and one which
requires closer monitoring and follow-up to reduce the risk
of adverse consequences.
Our study found that one in six adults aged 22 years and
older with co-occurring ASCVD and anxiety or depression
used SSRI and PAI in combination. Given the bleeding risk
reported by previous studies,20,21 our findings suggest that
alternatives to SSRIs need to be considered. However, all antidepressants are not equal in their potential impact on cardiovascular adverse events. Selective serotonin reuptake inhibitors
are generally considered safer than tricyclic antidepressants.34
Psychotherapy is another alternative that has been effectively
used to treat depression after an acute myocardial infarction,35
but psychotherapy is not widely used because of its limited
availability and affordability. For example, only 2.8% of a sample from a previous MEPS study used psychotherapy in 2007
for treatment of depression.36 Lack of available mental health
services was identified as a barrier to psychotherapy use by
21.6% of a surveyed sample of patients.37 In a 2009 survey of
mental health services use, 46% indicated that cost was the reason for not receiving mental health services.38 Therefore, the
physicians may need to individualize the treatment based on
the benefits and risks of SSRI/PAI combination use and the
patient’s financial situation.

5
The use of the SSRI/PAI combination was more likely
among older adults (>65 years) in both the unadjusted and
adjusted analyses. Increased age has a marked effect on
platelet function and mental health conditions including
depression and anxiety. Platelet function decreases with age
thus leading to an increased risk of thrombotic diseases.39
Additionally, elderly adults tend to be more reluctant to
report symptoms of depression thus present with more severe
disease requiring pharmacological intervention.40 Choosing
a treatment for ASCVD and depression or anxiety in elderly
patients need to be done with caution and take into account
their higher risk of thrombotic events.
In our study sample of adults with ASCVD and cooccurring anxiety of depression, there was a high prevalence of diabetes and/or hypertension and these individuals
were more likely to use SSRI and PAI in combination.
Patients with multiple chronic conditions or multimorbidity have complex medical needs41 in which prescribed
medications which could interact and this also affects
quality of life, work productivity, employability, and mortality.42 It is worth noting that in our study, a special type
of multimorbidity, the presence of both chronic physical
and mental health conditions, was also highly prevelant.41
This combination is important because mental health conditions such as depression can produce the greatest burden
compared to multimorbidity in chronic conditions without
depression.43 In the United States, the strategic framework
for improving health outcomes and quality of life among
those with multimorbidity calls for special attention to the
presence of both chronic physical and mental health conditions.44 Therefore, our findings highlight the need for a
team-based approach with physicians, mental health specialists, pharmacists, and case managers who can provide
support for prescription monitoring, patient awareness,
and education.
The significant association with diabetes diagnosis and
combined use of SSRI/PAI is important for two reasons: (1)
patients with diabetes already have increased risk for bleeding
relating to peptic ulceration45 and (2) low potency PAI (e.g.
aspirin and clopidogrel) may be less effective in these patients
thus requiring more potent agents (e.g. prasugrel and ticagrelor).46 Patients with multimorbidity (at minimum ASCVD,
diabetes, and anxiety or depression) are now at a potentially
greater risk for adverse effects associated with the medication
combination and may not be able to identify which medications are the offending agents. The prescriber now needs to
balance the harms and benefits of adding more potent PAIs to
the regimen for patients with diabetes and ASCVD. Another
chronic disease, hypertension, did have a significant association with treatment choice and was highly prevalent. This
association could also result from heart disease having treatments that overlap with hypertension treatment (e.g. betablockers or angiotensin-converting-enzyme inhibitors).
Strengths of this study include that it is based on physiologic and conceptual frameworks that attempted to address an
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Table 2. SSRI and PAI use among adults with co-occurring atherosclerotic cardiovascular disease and depression or anxiety: Medical
Expenditures Panel Survey, 2007, 2009, 2011, and 2013.
SSRI and PAI

All
Predisposing factors
Gender
  Female
  Men
Race/ethnicity
  White
  African American
  Others
Age (years)
  22–49
  50–64
  65
Enabling factors
Education level
   Less than high school
   High school graduate
   Greater than high school
Poverty level
   Poor (<100% of FPL)
   Near poor (100%–199% FPL)
   Middle income (200%–399% FPL)
   High income (400% or greater FPL)
Insurance coverage
  Private
  Public
  Uninsured
Prescription drug insurance
  Prescription coverage
   No prescription coverage
Need factors
Perceived physical health
   Excellent or very good
  Good
   Fair or poor
Perceived mental health
   Excellent or very good
  Good
  Fair poor
Diabetes
  Diabetes
  No diabetes
Hypertension
  Hypertension
  No hypertension
Personal health practices
Body mass index categories
   Underweight or normal
  Overweight
  Obese

SSRI or PAI

No SSRI and no PAI

N

Wt.%

N

Wt.%

N

Wt.%

Sig.

254

16.5

894

61.2

359

22.3

–

150
104

16.1
17.0

539
355

61.8
60.4

218
141

22.2
22.6

154
32
68

15.7
13.8
23.8

596
136
162

63.1
53.3
53.8

207
72
80

21.3
32.9
22.4

21
99
134

8.9
16.6
18.5

133
365
396

61.7
64.5
58.6

69
122
168

29.4
18.9
23.0

95
90
67

19.2
16.8
14.3

265
308
317

57.3
61.7
63.1

113
123
122

23.5
21.5
22.6

76
68
63
47

16.9
16.4
14.8
18.0

248
250
225
171

58.8
59.8
61.5
64.6

109
109
92
49

24.4
23.8
23.7
17.4

103
141
10

15.5
18.0
12.0

391
463
40

63.3
60.0
48.6

145
174
40

21.2
22.0
39.4

134
120

15.8
17.3

495
399

63.7
57.7

166
193

20.5
24.9

28
69
157

15.3
16.1
17.0

112
246
536

54.7
63.9
61.7

66
89
204

30.0
19.9
21.4

58
97
99

16.3
16.4
16.6

227
313
354

59.0
61.1
63.3

99
142
118

24.6
22.5
20.1

134
120

21.6
13.4

380
514

61.7
61.0

109
249

16.7
25.6

229
25

18.0
8.9

752
142

61.1
61.6

281
78

20.8
29.5

53
87
110

15.4
18.8
15.3

185
269
429

60.0
57.7
64.1

88
118
149

24.6
23.5
20.6

***

**

*

***

**
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Table 2. (Continued)
SSRI and PAI

Exercise frequency
   Three times per week or more
   Less than three times per week
Smoking status+
  Current smoker
   Former or non-smoker
External healthcare environment
Region
  Northeast
  Midwest
  South
  West

SSRI or PAI

No SSRI and no PAI

N

Wt.%

N

Wt.%

N

Wt.%

72
179

17.6
15.8

238
652

61.0
61.4

99
259

21.4
22.8

60
180

17.4
16.3

233
614

64.8
60.1

67
264

17.8
23.5

56
53
92
53

20.0
16.8
14.1
17.7

144
214
373
163

62.2
62.4
62.1
56.7

50
74
162
73

17.9
20.8
23.7
25.6

Sig.

FPL: Federal Poverty Line; PAI: platelet aggregation inhibitor; Sig.: significance; SSRI: selective-serotonin reuptake inhibitor; Wt.: weighted.
Based on adults aged 22 years and older with atherosclerotic cardiovascular disease and either depression or anxiety and without gastrointestinal bleeding disorders during 2007, 2009, 2011, and 2013. The percentage columns represent the weight row percentages for each group. Asterisks represent
significant group differences SSRI PAI use based on chi-square tests. Missing categories smoking and body mass index categories not presented.
***p < 0.001, **0.001 ⩽ p < 0.01; *0.01 ⩽ p < 0.05.

Table 3. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) from multinomial logistic on SSRI PAI use with co-occurring
atherosclerotic cardiovascular disease and depression or anxiety: Medical Expenditures Panel Survey, 2007, 2009, 2011, and 2013.
SSRI and PAI

Predisposing factors
Gender
  Male
  Female
Race/ethnicity
  White
  African American
  Others
Age (years)
  22–49
  50–64
  ⩾65
Enabling factors
Education level
   Less than high school
  High school
   Greater than high school
Poverty status
  Poor
  Near poor
  Middle income
  High income
Insurance coverage
  Uninsured
  Private
  Public

Sig.

No SSRI and no PAI

AOR

95% CI

AOR

95% CI

0.97

(0.69–1.36)

0.83

(0.59–1.17)

0.95
1.57

(0.62–1.44)
(0.98–2.53)

1.88
1.17

(1.27–2.79)
(0.75–1.83)

1.65
1.93

(0.90–3.04)
(1.08–3.45)

0.66
0.82

(0.42–1.05)
(0.54–1.25)

1.38
1.21

(0.91–2.11)
(0.79–1.84)

1.11
0.91

(0.75–1.65)
(0.63–1.31)

0.97
0.84
0.81

(0.55–1.71)
(0.50–1.42)
(0.49–1.35)

1.54
1.51
1.50

(0.89–2.67)
(0.95–2.38)
(0.95–2.37)

1.00
1.07

(0.40–2.52)
(0.43–2.68)

0.37
0.33

(0.21–0.68)
(0.19–0.56)

*

Sig.

**

**
***
(Continued)
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Table 3. (Continued)
SSRI and PAI

Prescription drug insurance
   No drug coverage
  Drug coverage
Need factors
Perceived physical health
   Excellent and very good
  Good
  Fair/poor
Perceived mental health
   Excellent and very good
  Good
  Fair/poor
Diabetes
  No diabetes
  Diabetes
Hypertension
  No hypertension
  Hypertension
Personal health practices
Body mass index categories
  Underweight/normal
  Overweight
  Obese
Exercise frequency
   Three or more times per week
  No exercise
Smoking status+
   Former or non-smoker
  Current smoker
External healthcare environment
Region
  Northeast
  Midwest
  South
  West

Sig.

No SSRI and no PAI

AOR

95% CI

AOR

95% CI

0.92

(0.62–1.36)

0.76

(0.53–1.07)

0.91
0.97

(0.54–1.54)
(0.58–1.63)

0.58
0.69

(0.35–0.95)
(0.43–1.10)

0.89
0.85

(0.54–1.48)
(0.52–1.38)

0.97
0.75

(0.65–1.44)
(0.48–1.18)

1.63

(1.15–2.31)

**

0.66

(0.47–0.92)

1.84

(1.04–3.27)

*

0.76

(0.54–1.08)

1.15
0.81

(0.77–1.72)
(0.54–1.23)

0.89
0.80

(0.59–1.34)
(0.54–1.18)

0.83

(0.56–1.23)

1.22

(0.85–1.75)

1.12

(0.73–1.72)

0.63

(0.44–0.92)

0.95
0.73
0.99

(0.60–1.50)
(0.45–1.17)
(0.58–1.67)

1.09
1.23
1.38

(0.63–1.86)
(0.77–1.99)
(0.81–2.35)

Sig.

*

*

*

FPL: Federal Poverty Line; PAI: platelet aggregation inhibitor; Sig.: significance; SSRI: selective-serotonin reuptake inhibitor; Wt.: weighted.
Based on adults aged 22 years and older with atherosclerotic cardiovascular disease and either depression or anxiety and without gastrointestinal bleeding disorders during 2007, 2009, 2011, and 2013. Asterisks represent significant group differences SSRI PAI compared to the reference group based on
multinomial logistic regression. Missing categories smoking and body mass index categories not presented.
***p < 0.001, **0.001 < p < 0.01; *0.01 ⩽ p < 0.05.

issue which occurs frequently when treating co-occurring
ASCVD and anxiety or depression and it was performed in a
real-world, nationally representative sample of the US population. Potential limitations to this study include that the
Multum Lexicon used to identify PAI does not include overthe-counter aspirin, a commonly used medication in this
class, but would include prescription aspirin. Long-term aspirin can be used to inhibit platelet aggregation. Additionally,
the Multum Lexicon used to identify SSRI is exclusive to that
class and does not include selective-norepinephrine reuptake

inhibitor (SNRI) medications. Finally, due to the cross-sectional study design, the timing of the different medications
and disease states could not be assessed. Future research
needs to explore the reasons for the combined use of SSRI
and PAI and its utility in a clinical setting.
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